Werewolf Therapeutics reports Q2 2021 net loss $10.9M; cash of $183.2M after IPO

Werewolf Therapeutics, Inc.

2021-Q2 EPS reported -$17.86

Completed May 2021 IPO: 7.5M shares at $16.00, net proceeds $109.2M.
Cash and cash equivalents $183.2M at June 30, 2021, up from $92.6M at Dec 31, 2020.
Q2 2021 net loss $10.9M vs $2.3M Q2 2020; R&D expenses $7.3M vs $3.8M.
Appointed Chulani Karunatilake as CTO and Mike Sherman to Board of Directors.
Existing cash expected to fund operations through at least Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.